PDCA对脑血管疾病继发肺部感染患者感染控制及生活质量的影响

目的考察PDCA对脑血管疾病继发肺部感染患者感染控制及生活质量的影响。方法选取2017年1月-2019年1月海南省人民医院收治的脑血管疾病继发肺部感染患者127例,随机分为试验组62例和对照组65例,对照组接受常规护理和治疗,试验组采取PDCA护理。酶联免疫吸附测定(ELISA)法测定血清白细胞介素-6(IL-6)、IL-8和肿瘤坏死因子-α(TNF-α)。记录患者肺部感染达到控制所需时间和病死率。记录患者治疗前后的生活质量。记录患者治疗结束后的满意度。结果试验组血清IL-6、IL-8和TNF-α分别为(20.45±3.63)pg/ml、(19.24±3.16)pg/ml和(61.34±7.12)pg/ml低于对照组(P<0.001);试验组肺部感染控制时间为(9.64±3.23)d短于对照组(P=0.002);试验组病死率为12.90%(8/62)低于对照组(P=0.042);治疗后,试验组生活质量评分为(232.13±17.14)分高于对照组(P<0.001);试验组总体满意度为96.77%高于对照组(P=0.001)。结论 PDCA循证干预可增强脑血管疾病后继发肺部感染患者的感染控制效果,提高患者生活质量。

Effect of PDCA on infection control and quality of life in patients with pulmonary infection secondary to cerebrovascular disease

OBJECTIVE To investigated the effect of PDCA evidence-based intervention on infection control and quality of life in patients with pulmonary infection secondary to cerebrovascular disease. METHODS A total of 127 patients with pulmonary infection secondary to cerebrovascular disease admitted to Hainan Provincial People′s Hospital from Jan. 2017 to Jan. 2019 were selected and randomly divided into 62 cases of experimental group and 65 cases of control group. The control group received routine nursing and treatment, and the experimental group received PDCA evidence-based intervention nursing. Serum interleukin-6(IL-6), interleukin-8(IL-8) and tumor necrosis factor-α(TNF-α) were measured by ELISA. The time required for the patients′ lung infection to reach control and the mortality of pulmonary infection were recorded. The quality of life was recorded before and after treatment. The satisfaction of patients after treatment was recorded. RESULTS The serum IL-6, IL-8 and TNF-α in the experimental group were(20.45±3.63)pg/ml,(19.24±3.16)pg/ml and(61.34±7.12)pg/ml, respectively, significantly lower than that of the control group(P<0.001). The control time of pulmonary infection in the experimental group was(9.64±3.23) d, significantly shorter than that of the control group(P=0.002). The mortality of the experimental group was 12.90%(8/62), significantly lower than that of the control group(P=0.042). After treatment, the score of quality of life of the experimental group was(232.13±17.14), which was significantly higher than that of the control group(P<0.001). The overall satisfaction of the experimental group was 96.77%, significantly higher than that of the control group(P=0.001). CONCLUSION PDCA evidence-based intervention can enhance the infection control effect of patients with secondary pulmonary infection after cerebrovascular disease, and improve the quality of life of patients.